-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$64.20144.85% Upside
Beam Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Beam Therapeutics Inc.?
Beam Therapeutics Inc. has been rated by research analysts at Stifel Nicolaus, Cantor Fitzgerald, BMO Capital, Citigroup, Credit Suisse in the past 90 days.